Thus, the lack of early BBB disruption in response to ET-1 provides in fact an argument that the BBB disruption induced by ET-1 in previous studies in vivo may have been secondary to ET-1-induced vasoconstriction and ischemia rather than due to a direct effect of ET-1 on the barrier. The gene discussed is EDN1; the disease is ischemia.